Business Model Breakdown
How Celanese Corp Makes Money
CE
Market Cap
$7.7B
Annual Revenue
$9.5B
Profit Margin
-12.2%
The Short Version
Celanese Corporation is a global chemical and specialty materials company that manufactures and sells a diverse portfolio of products used in a wide array of industrial and consumer applications. It primarily operates through two segments: the Acetyl Chain, which produces fundamental chemicals like acetic acid used in paints, coatings, textiles, and food, and Engineered Materials, which develops customized high-performance polymers for demanding applications in industries like automotive, medical, and electronics. The company generates revenue by selling these chemical intermediates and advanced materials to manufacturers worldwide, leveraging its proprietary technologies and global production scale.
Where the Revenue Comes From
Acetyl Chain products (e.g., acetic acid, VAM)
Engineered Materials products (e.g., performance polymers)
Who buys: Global industrial manufacturers across automotive, electronics, medical, consumer goods, construction, coatings, adhesives, and food & beverage sectors.
Why It Works (Competitive Advantages)
- ✔Leading positions in key product chains (e.g., Acetyl Chain)
- ✔Proprietary technology and intellectual property in specialty materials
- ✔Global scale and integrated production assets
- ✔Strong customer relationships due to switching costs of customized materials
Economic Moat: Narrow (Switching Costs, Intangible Assets/IP, Efficient Scale)
What Our Analysis Says
DVR Score as of May 3, 2026
Celanese (CE) is in an ongoing turnaround, but recent performance dampens the previously high conviction in a rapid recovery. The Q4 2025 EPS and revenue miss, alongside a negative net margin (-12.15%), indicate a slower path to profitability than anticipated. While the company forecasts improving earnings and positive free cash flow, and operational recoveries are underway (Frankfurt plant restart), analyst consensus has shifted to 'Hold' with a median price target below the current stock price. The stock hitting a 52-week high shows market optimism, yet the fundamental challenges suggest the ambitious 10x growth potential for this established specialty chemicals player is now a more distant and higher-risk proposition.